US-EU Index Rebalances / Quantitative Researcher, ORTEX

Dimitris Ioannidis

Index Rebalance professional of US, EU and Global Indices. Specialized in shareholder structure and index free float calculation, SPACs, quarterly rebalance predictions of US-EU indices and cross-index implications of corporate actions such as M&A's, Spin-offs and IPOs.

All forecasts and calculations are estimates derived from a combination of public sources considered reliable. These sources include, but are not limited to, exchange and regulatory filings, company announcements, and ETFs. While best efforts are made to maximize accuracy, estimates and predictions are subject to uncertainty.

No index data are used.

US-EU Index Rebalances / Quantitative Researcher

STOXX Europe600 Dec25 Forecast: VSURE, VEND & MTLN Leading Top Additions

Metlen Energy & Metals — Sights set for London and €2bn/year EBITDA

Global Financial Data and Analytics Platform

ORTEX

ORTEX is a global financial data and analytics platform providing real-time securities lending and short interest data, index rebalance data, holdings and insider transactions, trading signals, corporate actions and news,  stock machine learning and factor scores and other analytics. The majority of the data are downloadable and accessible through APIs.

Index Rebalance

<ul>
<li>
<a href="https://www.smartkarma.com/entities/mytilineos-holdings-sa" target="_blank" data-smartkarma-citation="entities:25114:1" rel="noopener">Mytilineos Holdings Sa (MYTIL GA)</a> is projected to be added to F100 following its change of incorporation and primary listing from Greece to UK.</li>
<li>A methodology change in currency trading requirements is expected to result in <a href="https://www.smartkarma.com/entities/princess-private-equity-holdin" target="_blank" data-smartkarma-citation="entities:22083:1" rel="noopener">Partners Group Private Equity (PEY LN)</a> and <a href="https://www.smartkarma.com/entities/biopharma-credit-plc-fund" target="_blank" data-smartkarma-citation="entities:28317:1" rel="noopener">BioPharma Credit PLC (BPCR LN)</a> entering F250.</li>
<li>
<a href="https://www.smartkarma.com/entities/oakley-capital-investments-limited" target="_blank" data-smartkarma-citation="entities:23334:1" rel="noopener">Oakley Capital Investments (OCI LN)</a> is expected to be included in F250 following its listing transfer from AIM to the Main market of the LSE.</li>
</ul>



Mytilineos Holdings Sa (MYTIL GA) is projected to be added to F100 following its change of incorporation and primary listing from Greece to UK.
A methodology change in currency trading requirements is expected to result in Partners Group Private Equity (PEY LN) and BioPharma Credit PLC (BPCR LN) entering F250.

Oakley Capital Investments (OCI LN) is expected to be included in F250 following its listing transfer from AIM to the Main market of the LSE.


UK Index September 2025 Forecast: Greece in F100 & Other New Candidates in F250